Skip to content

U-100 unit conversion

BPC-157 calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

8.3U-100 units · 0.083 mL

30 mcg per unit · 3000 mcg/mL

How the calculator works, sources and review dates

BPC-157 math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 6 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-15. source-curated; clinician review pending.

Units chart for listed BPC-157 sizes

U-100 math for listed BPC-157 sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
6 mg603020
10 mg1005033.3
20 mg20010066.7

What is BPC-157?

Sellers list BPC-157 as vials, sprays, and capsules. A listing is a listing. It does not prove every form matches the material in a paper. Lab work has looked at tissue repair, growth-factor, and nitric-oxide pathways. Those ideas stay ideas until a controlled human study of the same preparation answers a clinical question.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Clinical observation

2021 clinician-reported knee-pain series

17 charts, 16 telephone respondents with varied knee pain causes.

Reported findings. 11 of 12 BPC-only respondents reported knee-pain improvement; 3 of 4 in the BPC plus TB4 group reported improvement.

Nonresponse. One BPC-only respondent and one combination respondent reported no improvement; one of 17 chart patients could not be contacted.

Harms. Adverse effects were not systematically established by this retrospective telephone follow-up.

Limits. Uncontrolled retrospective review, variable follow-up, no validated functional outcomes or MRI repair evidence. Counts describe this selected series, not population success rates.

Preparation: BPC-157 alone or with TB4; TB4 formulation unspecified, not proof for TB-500 fragment. Route: intra-articular knee administration

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Regulatory context

FDA 2026 briefing: human studies and adverse reports

FDA synthesis of small studies and FAERS/HFCS reports through December2025; not a representative treated population.

Reported findings. FDA described small human studies, including knee-pain outcomes; the original outcome series is recorded separately rather than counted again.

Nonresponse. No representative treatment-response denominator. Briefing recommendations concern compounding and ulcerative colitis, not proof of ineffectiveness for every condition.

Harms. FDA summarized three injectable FAERS reports: injection-site reaction, shortness of breath and pigmentation changes. Concomitant thymosin, BPC/TB500 combination exposure or incomplete case information limits attribution. Three HFCS cases also involved multi-ingredient products and incomplete information. These reports establish neither BPC-specific causation nor event rates.

Limits. Small studies and unclear safety monitoring leave long-term safety uncertain. FDA discussed potential impurity, aggregation and immunogenicity risks, dependent on preparation and route. This is a May2026 agency evaluation for an advisory meeting, not a final regulatory determination.

Preparation: FDA evaluation of BPC-157 free base and acetate; reported products often have uncertain salt, purity or combination identity. Route: Injectable spontaneous reports; reviewed clinical studies used several different routes.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human report

BPC-157 public thread: selected relief, nonresponse and mood-related reports

Selected anonymous comments in one public thread, retained as one aggregate source group, not one person or an enumerated cohort.

Reported findings. One selected commenter responding to the no-anhedonia prompt reports knee-pain relief. Other thread comments describe relief or no mood change; these are self-reports.

Nonresponse. A different selected commenter describes six months of oral then three months of injected use without observable benefits or side effects. This is one account, not a controlled comparison between routes or a nonresponse rate.

Harms. One selected comment attributes anhedonia to BPC-157; another reports anxiety lasting about a week and stopping use. These are reported temporal associations without clinical causal adjudication.

Limits. One conservative thread-level report group. The author posted both opposing voting prompts; those prompts are not two exposure reports. Votes and selected comments cannot establish participant counts, success rates or adverse-event prevalence. Routes, exposure duration and co-interventions stay attached to their own commenters. The thread includes other compounds and medications; their roles in causing or preventing reported mood changes are unresolved. No verified diagnoses, analytical preparation check, controlled comparator or independently adjudicated outcomes. Subjective relief is not verified tissue repair. Exact parent/comment creation and edit timestamps are unknown; relative ages and footer dates are not assigned as publication dates. Browser rendering may be cached. Parent raw retrieval returned HTTP 403; selected-comment raw retrieval was not attempted. Automatic availability and original-body fingerprints remain unresolved. The selected comment citations belong to this same thread-level group and are not separately counted as independent reports here.

Preparation: Public commenters describe BPC-157 exposure; preparations unspecified and co-use varies by account. Route: Mixed oral, injected and unstated routes in the thread; each route belongs only to the commenter who states it.

Read original source ↗

Editorial review 2026-10-15. Clinician review pending.

Clinical observation

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

Two previously exposed adults, very short follow-up

Reported findings. No efficacy outcome established

Nonresponse. Not an efficacy trial

Harms. No reported short-term changes in tested safety measures; rare/long-term harms unresolved

Limits. No transfer to other routes/formulations/indications; clinician review pending.

Preparation: BPC-157 pilot preparation Route: intravenous

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human report

Andrew Huberman · Modern Wisdom #1150

One public speaker self-report; no population denominator.

Reported findings. Huberman reported disappearance of shoulder pain after BPC-157.

Nonresponse. Not reported in reviewed excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Self-report with exercise context and stated placebo uncertainty. Pain relief is not tissue repair. Original audio not independently listened to.

Preparation: Reported name; exact formulation unverified. Route: Unknown in account; do not reconstruct.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human report

Jeremy Renner · JRE #2312

One public speaker self-report; no population denominator.

Reported findings. Renner described BPC-157 among multiple recovery interventions.

Nonresponse. Not reported in reviewed excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Recall incomplete; rehabilitation, hyperbaric and red light co-occurred. Assisted walking is not full recovery. Original audio not independently listened to.

Preparation: Reported name; exact formulation unverified. Route: Unknown in account; do not reconstruct.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Clinical observation

Rising Use of Unapproved BPC-157 and Associated Patient-Reported Outcomes Curated from Clinical Notes

1039 documented users in U.S. clinical notes; 354 with directional outcomes

Reported findings. Among 354 patients with a documented directional outcome, 279 had an improvement report: 263 patient-reported and 16 clinician-observed. This is not verified tissue repair.

Nonresponse. 58 unchanged, 17 worse, 685 without outcome direction; 21 discontinuations attributed to perceived ineffectiveness. Selected documented reports, not population efficacy.

Harms. 24 of 129 discontinuations involved adverse effects; neuropsychiatric, injection-site and GI events reported without causal adjudication.

Limits. Preprint, not peer reviewed. LLM extraction with sampled physician validation; individual notes and analysis code unavailable. 525 co-used other therapies. Results oral 180 / SC 141 / IM 15 / unknown 652 leave 51 unreconciled; discussion incorrectly calls SC most common. No route-specific estimate. Directional-response extraction accuracy was 88.2% in a sampled, nonblinded physician review; 78.4% concerned benefit-type extraction, a separate task. Browser review reconfirmed these counts; direct raw retrieval returned an interstitial challenge. Neither selected reports nor incomplete outcomes establish a population success rate or causal effectiveness.

Preparation: Documented BPC-157 use, products/adherence unverified Route: Mixed oral/SC/IM and unknown routes; source counts inconsistent

Read original source ↗

Editorial review 2026-10-15. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No US therapeutic product approval is established by this curated source set; other countries and products may differ.

Compounding

not established. FDA’s July 2026 advisory briefing recommended against 503A inclusion. An advisory recommendation is not a final rule, product approval or determination of every pharmacy’s eligibility.

Research

investigational. Early human observational reports and extensive preclinical hypotheses; controlled clinical benefit remains unresolved.

Sport

prohibited. WADA S0 names BPC-157 as prohibited at all times.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

The vendor file lists 6 mg, 10 mg, and 20 mg labels. Follow the label on the vial you actually hold for temperature and light. This page does not set a throw-away date after you add water. Write the lot.

Risks and mix-ups already on the record

  • Safety is incomplete; absence of reports does not establish safety.
  • FDA’s 2026 review includes reported local reactions, breathing difficulty and pigmentation changes. Concomitant products and missing details limit attribution; reporting data cannot estimate incidence.
  • Unknown or incomplete for research formulations; this is not a clearance for use.
  • Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Dated pain, daily function, rehabilitation and activity records alongside existing clinician-directed observations. Record mood changes and symptoms as observations, including nonresponse; improvement does not establish structural tissue healing.

Sources

  1. Primary evidence or regulator source · checked 2026-10-09
  2. WADA prohibited list · checked 2026-10-09
  3. 2021 clinician-reported knee-pain series · checked 2026-10-09
  4. FDA 2026 briefing: human studies and adverse reports · checked 2026-10-09
  5. Community reports: improvement, nonresponse and mood symptoms · checked 2026-10-09

Questions people ask

Is BPC-157 FDA-approved?

This source set shows no US drug approval as of Oct 9, 2026. FDA has published compounding-safety materials that mention BPC-157. That is not product approval.

How many units is a listed 10 mg vial after 2 mL of water on a U-100 syringe?

If you type 10 mg and 2 mL, a U-100 syringe has 100 marks per mL, so each unit is 50 mcg of the dissolved mass. The calculator does that math on the numbers you type. It does not pick an amount for you.

How many units is a listed BPC-157 vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.